Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 207 results for arthritis

  1. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  2. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 TS ID 11848

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development [GID-TA10598] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued [GID-TAG400]

    Technology appraisal guidance
    Discontinued

  5. Osteoarthritis in over 16s (QS87)

    This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    19 October 2022
    View quality statements

    Sections for QS87

  6. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  7. Total prosthetic replacement of the temporomandibular joint (IPG500)

    Evidence-based recommendations on total prosthetic replacement of the temporomandibular joint. This involves replacing the joint with an artificial one.

    Interventional procedures guidance
    Published
    27 August 2014
    View recommendations

    Sections for IPG500

  8. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals

  9. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  10. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued [GID-TA10180]

    Technology appraisal guidance
    Discontinued

  11. Rapid escalation to systemic treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are there any clinical (for example demographic or phenotypic) or laboratory (for example genetic or immune) biomarkers that can be used to identify those most likely to benefit from this treatment approach?

    long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are...

    Research recommendation
    Published
    9 June 2015

  12. Joint distraction for knee osteoarthritis without alignment correction (IPG529)

    Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.

    Interventional procedures guidance
    Published
    23 July 2015
    View recommendations

    Sections for IPG529

  13. Committee D members

    Find out more about NICE technology appraisals advisory committee D members

  14. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued [GID-TA11108]

    Technology appraisal guidance
    Discontinued

  15. Shoulder resurfacing arthroplasty (IPG354)

    Evidence-based recommendations on shoulder resurfacing arthroplasty. This involves reshaping the upper arm bone and placing an artificial shoulder joint onto it.

    Interventional procedures guidance
    Published
    28 July 2010
    View recommendations

    Sections for IPG354